Juvenile Arthritis News

Skin disease is more active than muscle disease in juvenile dermatomyositis and should be treated early and aggressively to limit its severity, according to a study.

To avoid perpetuating misinformation regarding rheumatic diseases, rheumatologists should ensure they are aware of the available evidence – or lack thereof – for some of the popular myths patient hold about their disease, noted a speaker at the EULAR 2021 Congress.

Patients who received rheumatology care from nurse practitioners or physician assistants rated their overall experience similarly to those who saw a rheumatologist, according to survey data published in Arthritis Care & Research.

Routine care for inflammatory arthritis should include self-management strategies that feature problem-solving, goal-setting and, if possible, cognitive behavioral therapy, according to new EULAR recommendations.

Secukinumab yielded a significantly longer time to flare than placebo in pediatric patients with enthesitis-related arthritis and juvenile psoriatic arthritis, according to findings presented at the EULAR 2021 Congress.

Approximately 70% of patients with juvenile idiopathic arthritis who are re-treated with etanercept achieve inactive disease status 12 months after receiving the second course, according to data published in Arthritis Research & Therapy.

Findings from the Live Yes! INSIGHTS survey from the Arthritis Foundation showed that out of some 40,000 patient responses, 100% reported experiencing some kind of pain within the last 7 days.

The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market.

There is no association between a child’s ethnicity and the risk for neonatal lupus erythematosus, nor for any specific disease symptoms, according to data published in The Journal of Rheumatology.

Parents reported that two-thirds of children with juvenile idiopathic arthritis demonstrate drug side effects that impact their quality of life within 1 year of diagnosis, according to data published in Arthritis Care & Research.